Aptevo files prospectus supplement for up to $2,309,834 ATM common-stock offering
On October 30, 2026, Aptevo Therapeutics filed a prospectus supplement under its effective Form S-3 registration statement to sell common stock from time to time with an aggregate offering price of up to $2,309,834 under an existing ATM Sales Agreement. Roth Capital Partners, LLC is the sales agent, and the company reported that it had issued and sold 303,157 shares under the Sales Agreement and Prior Prospectus for $11.8 million in aggregate gross proceeds as of the prospectus supplement date.
Key takeaways
ATM capacity: The prospectus supplement covers common stock with an aggregate offering price of up to $2,309,834.
Sales agent: Roth Capital Partners, LLC acts as sales agent under the April 28, 2025 ATM Sales Agreement.
Prior ATM sales: Aptevo had issued and sold 303,157 shares for $11.8 million in aggregate gross proceeds as of the prospectus supplement date.
Registration: The shares are offered under Form S-3 File No. 333-284969, declared effective February 26, 2025; the shelf permits up to $100,000,000 of securities.
Legal opinion: Paul Hastings LLP opined that, subject to its assumptions and qualifications, the shares are duly authorized and will be validly issued, fully paid, and nonassessable upon issuance, delivery, and payment.
Disclosed terms: No share price, sales-agent commission, or use of proceeds is stated in the supplied filing text.
Key metrics
Primary source
TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.
Open SEC filingFollow APVO in real time
Get material earnings, filing, IR, and earnings-call alerts by email.